Pharmafile Logo
Pharmafocus logo
Advanced Search

Crohn’s disease

Showing 15 posts of 35 posts found.

european_commission_web

Takeda and TiGenix’s Alofisel becomes first donor-derived stem cell therapy approved in Europe

March 26, 2018
Sales and Marketing Crohn’s disease, EU, Europe, European Commission, Takeda, TiGenix, crohn's disease, pharma

The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell (eASC) therapy Alofisel (darvadstrocel) for …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal

October 30, 2017
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

News
pfizer-building-logo1web

Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

October 30, 2017
Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …

News

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

May 3, 2017
Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …

News
celgene_1_02

Celgene trial displays promising results for Crohn’s disease alternative treatment

October 17, 2016
Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial

Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …

News
medimmune

AstraZeneca agrees $250 million licensing agreement with Allergan

October 3, 2016
Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease

Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …

News
janssen_latest_logo_on_sign

Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials

May 26, 2016
Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial

Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials.  The company said a significant …

News
janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016
Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …

News

TiGenix says additional data for stem cell product affirms safety profile

March 9, 2016
Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial

Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …

News
Janssen image

Janssen, Enterome and Kymab in research collaborations

January 7, 2016
Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research

Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …

News
Janssen image

Janssen submits Stelara for EU approval for Crohn’s

December 9, 2015
Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab

Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …

News
Stelera

Encouraging late-stage results for Stelara in Crohn’s disease

October 21, 2015
Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelera, crohn's disease, ustekinumab

Janssen is planning new regulatory submissions for Stelera after Phase III data found it improved responses and remission rates in …

News
Celgene

Celgene to acquire Receptos in $7.2bn deal

July 15, 2015
Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis

Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …

News
Entyvio

NICE u-turns on Entyvio for Crohn’s disease

July 10, 2015
Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding

NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …

News
Lonza image

TiGenix and Lonza partner on stem cell manufacturing

February 13, 2015
Manufacturing and Production, Sales and Marketing Crohn’s disease, Lonza, Stem cells, TiGenix, crohn's disease, eascs, manufacturing, spa

Stem cell therapy developer TiGenix has enlisted the help of biologics manufacturer Lonza to produce its medicine Cx601 for late-stage …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026